Quince Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | ||
|---|---|---|
| PART I. · FINANCIAL INFORMATION | ||
| Item 1. | Financial Statements (Unaudited) | 1 |
| Condensed Consolidated Balance Sheets (Unaudited) | 1 | |
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) | 2 | |
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) | 3 | |
| Condensed Consolidated Statements of Cash Flows (Unaudited) | 4 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 5 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 27 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 35 |
| Item 4. | Controls and Procedures | 35 |
| PART II. | OTHER INFORMATION | |
| Item 1. | Legal Proceedings | 36 |
| Item 1A. | Risk Factors | 36 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 37 |
| Item 3. | Defaults Upon Senior Securities | 37 |
| Item 4. | Mine Safety Disclosures | 37 |
| Item 5. | Other Information | 37 |
| Item 6. | Exhibits | 38 |
| Signatures | 40 | |
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "expect," "objective," "plan," "potential," "seek," "grow," "target," "if," and similar expressions intended to identify forward-looking statements.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other filings with the Securities and Exchange Commission (the "SEC"). It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:
our ability to successfully execute on our current strategic direction, including our ability to pursue strategic alternatives, such as completing a reverse merger or selling assets;
our financial performance;
our ability to continue as a going concern, the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and debt service requirements;
the accuracy of our estimates regarding expenses, liquidity requirements, and needs for additional financing;
our expectations related to the use of our available cash;
our ability to obtain funding for our operations;
our ability to attract and retain key personnel;
our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;
potential claims relating to our intellectual property; and
our ability to maintain compliance with Nasdaq listing requirement.
We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.
You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or revised expectations.
You should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.
This Quarterly Report on Form 10-Q contains estimates, projections and other information concerning our industry, our business and the markets for our drug candidates. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.
DEFINED TERMS
Unless the context requires otherwise, references to “Quince,” “the Company,” “we,” “us,” or “our” in this Quarterly Report on Form 10-Q refer to Quince Therapeutics, Inc. and its consolidated subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below.
| Abbreviated Term | Defined Term |
|---|---|
| AIDE | Autologous Intracellular Drug Encapsulation |
| ASC | Accounting Standards Codification |
| ASU | Accounting Standards Update |
| A-T | Ataxia-Telangiectasia |
| the Code | Internal Revenue Code of 1986, as amended |
| CODM | Chief Operating Decision Maker |
| Debt Agreement | Unsecured line of credit agreement between EryDel and the European Investment Bank, which the Company guaranteed on October 20, 2023 in connection with the EryDel Acquisition |
| DSP | Dexamethasone Sodium Phosphate |
| EC | European Commission |
| EryDel | Quince Therapeutics, S.p.A (previously named EryDel S.p.A.) |
| eDSP | Encapsulated dexamethasone sodium phosphate encapsulated in patient's own red blood cells (previously referred to as EryDex) |
| eDSP System | Automated combination product to encapsulate dexamethasone sodium phosphate in red blood cells |
| EIB | European Investment Bank |
| EU | European Union |
| EIB Loan | Unsecured line of credit between EryDel and the European Investment Bank |
| Exchange Act | Securities Exchange Act of 1934, as amended |
| FASB | Financial Accounting Standards Board |
| FDA | United States Food and Drug Administration |
| GAAP | generally accepted accounting principles in the United States |
| ICARS | International Cooperative Ataxia Rating Scale |
| IPR&D | In-process Research and Development |
| Lighthouse | Lighthouse Pharmaceuticals, Inc. |
| Nasdaq | The Nasdaq Stock Market LLC |
| NDA | New Drug Application |
| NEAT | eDSP Phase 3 Clinical Trial (Neurological Effects of eDSP on Subjects with A-T) |
| Novosteo | Novosteo, Inc. |
| OLE | Open-Label Extension Clinical Trial |
| R&D | Research and Development |
| RSU | Restricted Stock Units |
| Sarbanes-Oxley Act | The Sarbanes-Oxley Act of 2002 |
|---|---|
| SEC | United States Securities and Exchange Commission |
| Securities Act | Securities Act of 1933 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.